Beneficial effect of erythropoietin on experimental allergic encephalomyelitis
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We have known for a long time that erythropoietin signaling plays a key role in bone marrow erythrocyte proliferation. However, recent studies have indicated that erythropoietin also may have protective effects on the nervous system. This unexpected role remains incompletely characterized. To investigate the potential neuroprotective role of erythropoietin in the central nervous system, we assessed its effects on a well‐characterized autoimmune demyelinating model of multiple sclerosis–myelin oligodendrocyte glycoprotein‐induced experimental autoimmune encephalomyelitis (EAE) in the mouse. We found that erythropoietin administered intravenously for 14 days after the onset of symptoms reduced both disease severity and duration of maximum impairment at dose levels as low as 50U/kg (p < 0.001). We assessed the neuropathology of diseased spinal cords and found that erythropoietin‐treated EAE animals had reduced axonal damage, inflammatory cell infiltration and demyelination, and diminished blood–brain barrier leakage when compared with saline‐treated EAE controls. Moreover, the pronounced upregulation of spinal cord major histocompatibility complex (MHC) class II expression found in saline‐treated EAE was significantly reduced in erythropoietin‐treated animals, a finding we replicated in vitro, using microglial cultures. The notion that short‐term erythropoietin therapy might be of clinical benefit in human autoimmune demyelinating diseases needs investigation. Ann Neurol 2004; 56: 767‒777
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bjartmar, C., Wujek, J. R., & Trapp, B. D. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00069-2 · Cited by 573 · cited 1×
“Although the exact cause of axonal injury in EAE is unknown, numerous factors have been implicated including inflammatory cytokines, glutamate excitotoxicity, and nitric oxide.(24,25) Thus, mediators, secreted by either activated glial cells or T cells, may be key players that contribute to axonal injury in EAE, and s…”
Background
Cited by
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Chougule, M. B., Shoyele, S. A., & Alexander, A. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.05.011 · Cited by 630
Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
Friese, M. A., Schattling, B., & Fugger, L. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.37 · Cited by 628
Emerging biological roles for erythropoietin in the nervous system
Brines, M., & Cerami, A. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1687 · Cited by 523
The blood–spinal cord barrier: Morphology and Clinical Implications
Bartanusz, V., Jezova, D., Alajajian, B., & Digicaylioglu, M. (2011) · Annals of Neurology · doi:10.1002/ana.22421 · Cited by 481
Metadata
- Authors
- Li, W., Maeda, Y., Yuan, R. R., Elkabes, S., Cook, S., & Dowling, P.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2004-11-23
- Volume
- 56
- Issue
- 6
- Pages
- 767-777
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W1983925588
- Cited by
- 102
- References
- 1
- FWCI
- 4.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. https://app.cochat.ai/papers/10.1002/ana.20274
- The paper
- Li, W., Maeda, Y., Yuan, R. R., Elkabes, S., Cook, S., & Dowling, P. (2004). Beneficial effect of erythropoietin on experimental allergic encephalomyelitis. Annals of Neurology. https://doi.org/10.1002/ana.20274
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.